Delving into the Latest Updates on Ancestim with Synapse

Overview

Basic Info

Drug Type

Colony-stimulating factors

Synonyms

Ancestim (USAN/INN), Ancestim (genetical recombination) (JAN), Human SCF

+ [5]

Target

CSF-3R

Mechanism

CSF-3R agonists(Colony stimulating factor 3 receptor agonists), Stem cells stimulants

Therapeutic Areas

Other Diseases

Active Indication

Hematopoietic stem cell transplantation

Inactive Indication-

Originator Organization

Amgen, Inc.

Active Organization

Amgen, Inc.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

AU (09 Aug 1999),

Hematopoietic stem cell transplantation

RegulationOrphan Drug (US)

Login to view timeline

Gene Sequence

Sequence Code 16915307

Source: *****

Some drugs have the ability to push stem cells (the cells responsible for producing new cell types) out of the bone marrow and into the blood stream. The steps involved in this process are still poorly understood. However, a better understanding of this process could lead to improved results in transplantation, cancer treatment, and contribute to the development of new genetic therapies for a wide variety of disorders.
In this study researchers plan to compare two different treatments, both that mobilize (push) stem cells out of the bone marrow into the blood stream. In addition, researchers will attempt to determine which is the most efficient at mobilizing blood cells of patients with multiple myeloma.
Information and knowledge gained from this study will help to design future transplantation and genetic therapy research studies.

Start Date01 Sep 1998

Sponsor / Collaborator

National Heart, Lung & Blood Institute

100 Clinical Results associated with Ancestim

Login to view more data

100 Translational Medicine associated with Ancestim

Login to view more data

100 Patents (Medical) associated with Ancestim

Login to view more data

939

Literatures (Medical) associated with Ancestim

06 Nov 2024·Journal of Agricultural and Food Chemistry

Alpha Hydroxyl Acids from Mume Fructus and Schisandrae Chinensis Fructus Prevent Obesity by Inhibiting Intestinal Lipase in Diet-Induced Obese Mice

Article

Author: Deng, Ying ; Wang, Chao ; Tian, Yan ; Liang, Guobiao ; Ma, Xiaochi ; Wang, Jiayue ; Zhang, Baojing ; Wang, Yan ; Feng, Lei ; Li, Dawei

Restriction of lipid uptake and absorption from the diet is regarded as an efficient strategy for the management of obesity, while lipase inhibition could successfully block the digestion of dietary lipids. Mume Fructus (MF) and Schisandrae Chinensis Fructus (SCF) were used as fruits, the biological effect of which on obesity desired more attention. Herein, the extracts of MF and SCF displayed significant efficacy in managing obesity in mice fed with a high-fat diet, via the inhibition of hydrolase activity of lipase in the digestive tract. Using the bioactivity guidance strategy, citric acid and malic acid were identified as the major lipase inhibitors from MF and SCF, respectively, which could prevent body weight gain, along with adipose tissue formation, and alleviate hyperlipidemia and hepatic steatosis in obese mice. Above all, MF and SCF could be used for the management of obesity via the lipase inhibition by citric acid and malic acid, displaying potential applications in healthy foods, nutritional supplements, and pharmaceutical materials.

01 Nov 2024·International Journal of Biological Macromolecules

Textural enhancement and glycemic potency reduction of sugarcane fiber-incorporated white bread with ascorbic acid and xanthan gum

Article

Author: Taheri, Afsaneh ; Abdul Halim, Fatin Natasha Binte ; Halim, Fatin Natasha Binte Abdul ; Du, Juan

In this study, ascorbic acid (0.02 % w/w), xanthan (0.75 % or 1.5 % w/w), and their combination have been added into sugarcane fiber (SCF) incorporated (5 % or 10 % w/w) wheat flour-based white breads. The effects of different additives on the physical characteristics, and the in-vitro and in-vivo glycemic potency of breads were evaluated. Addition of xanthan alone and the combination of additives reduced hardness and increased specific volume. SEM images showed that xanthan caused larger, more uneven holes in breadcrumbs due to xanthan's high elasticity and viscosity. FTIR spectrum indicated that the combination of SCF, xanthan, and ascorbic acid resulted in higher β-turn, lower α-helix protein structures, and lower ratios of α-helix/β-sheet, indicating a more flexible gluten structure formed. In-vitro digestibility results suggested that all SCF-incorporated breads had a lower glycemic index (GI) value than reference. Samples with 0.02 % (w/w) ascorbic acid and 1.5 % (w/w) xanthan reported the lowest in-vitro and in-vivo GI values.

01 Oct 2024·EFSA Journal

Re‐evaluation of argon (E 938) and helium (E 939) as food additives

Article

Author: Multari, Salvatore ; Houdeau, Eric ; Aquilina, Gabriele ; Bastos, Maria ; Gundert-Remy, Ursula ; Castle, Laurence ; Rasinger, Josef Daniel ; Gürtler, Rainer ; Kurek, Marcin ; Boon, Polly ; Andreassen, Monica ; Morales, Patricia ; Grasl-Kraupp, Bettina ; Smeraldi, Camilla ; Frutos Fernandez, Maria Jose ; Frutos Fernandez, Maria Jose ; Gundert‐Remy, Ursula ; Louro, Henriqueta ; Passamonti, Sabina ; Gurtler, Rainer ; Fitzgerald, Reginald ; Grasl‐Kraupp, Bettina ; Fallico, Biagio ; EFSA FAF Panel ; Rincon, Ana Maria ; Vermeiren, Sam

Abstract The Panel on Food Additives and Flavourings (FAF) provides a scientific opinion re‐evaluating the safety of the two food additives argon (E 938) and helium (E 939). Argon (Ar) and helium (He) are two noble gases, highly stable single atoms. Their chemical inertness is well known. Their physicochemical properties have served as a basis for their previous evaluations by SCF and JECFA, which have considered the use of these food additives safe even in the absence of a toxicological evaluation. No business operator or other interested party provided information in response to the call for data published by EFSA to support the re‐evaluation of these two food additives with respect to their identity and specifications, manufacturing process (including the identification and quantification of potential impurities) and how they are applied to food to exert their technological function. One business operator replied to the call for data issued by EFSA reporting use levels of E 938 as a packaging gas in one food category. Based on their physicochemical properties, both gases are considered by the Panel to be of low toxicological concern when used as food additives. No information was available on the potential presence of impurities of toxicological concern resulting from the manufacturing process(es) applied to the production of the food additives E 938 and E 939. The Panel however noted that a minimum purity of 99.0% is required to comply with existing specifications. The Panel concluded that the use of argon (E 938) and helium (E 939) as food additives does not raise a safety concern. The Panel recommended an amendment of the existing EU specifications to introduce the respective CAS numbers.

100 Deals associated with Ancestim

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D02937	Ancestim	L03AA12	DB09103

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Hematopoietic stem cell transplantation	AU	Amgen, Inc.	09 Aug 1999

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASCO2004	Not Applicable	Relapsed Solid Neoplasm	-	rhTPO	(ivkkonnrpv) = hshplxairh wahebytuss (gmqqiwyjsw ) View more	-	15 Jul 2004
				rhIL-11 + G-SCF	(ivkkonnrpv) = cxhnlfilel wahebytuss (gmqqiwyjsw ) View more